Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Justus Duyster

Showing results (31-40 of 248) with videos related to

Pageof 25
Sort By:
Clinical Chemistry and Laboratory Medicine|January 19, 2017
Early mixed hematopoietic chimerism detection by digital droplet PCR in patients undergoing gender-mismatched hematopoietic stem cell transplantationMiguel Waterhouse, Dietmar Pfeifer, Marie Follo, et al.
Blood|July 1, 2011
An RNAi-based system for loss-of-function analysis identifies Raf1 as a crucial mediator of BCR-ABL-driven leukemogenesisCorinna Albers, Anna L Illert, Cornelius Miething, et al.
Bone Marrow Transplantation|November 20, 2024
Immunological reconstitution and infections after alloHCT - a comparison between post-transplantation cyclophosphamide, ATLG and non-ATLG based GvHD prophylaxisThomas Meyer, Kristina Maas-Bauer, Ralph Wäsch, et al.
Clinical Biochemistry|November 29, 2017
Cell-free DNA characteristics and chimerism analysis in patients after allogeneic cell transplantationJesus Duque-Afonso, Miguel Waterhouse, Dietmar Pfeifer, et al.
Annals of Hematology|March 3, 2016
Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCRMiguel Waterhouse, Marie Follo, Dietmar Pfeifer, et al.
Plos One|November 3, 2011
Differential sensitivity of ERBB2 kinase domain mutations towards lapatinibRama Krishna Kancha, Nikolas von Bubnoff, Natalie Bartosch, et al.
Leukemia Research|April 28, 2004
Imatinib mesylate (STI571) prevents the mutator phenotype of Bcr-Abl in hematopoietic cell linesHeiko van der Kuip, Alexandra Moehring, Lara Wohlbold, et al.
Haematologica|August 30, 2008
Imatinib and leptomycin B are effective in overcoming imatinib-resistance due to Bcr-Abl amplification and clonal evolution but not due to Bcr-Abl kinase domain mutationRama Krishna Kancha, Nikolas von Bubnoff, Cornelius Miething, et al.
Annals of Neurology|October 3, 2009
Primary central nervous system lymphoma in a patient treated with natalizumabAndreas Schweikert, Marcus Kremer, Florian Ringel, et al.
Molecular Oncology|December 17, 2023
A newly identified 45-kDa JAK2 variant with an altered kinase domain structure represents a novel mode of JAK2 kinase inhibitor resistanceSivahari Prasad Gorantla, Tony Andreas Mueller, Corinna Albers-Leischner, et al.
Pageof 25

Showing results (31-40 of 248) with videos related to

Sort By:
Pageof 25
Clinical Chemistry and Laboratory Medicine|January 19, 2017
Early mixed hematopoietic chimerism detection by digital droplet PCR in patients undergoing gender-mismatched hematopoietic stem cell transplantationMiguel Waterhouse, Dietmar Pfeifer, Marie Follo, et al.
Blood|July 1, 2011
An RNAi-based system for loss-of-function analysis identifies Raf1 as a crucial mediator of BCR-ABL-driven leukemogenesisCorinna Albers, Anna L Illert, Cornelius Miething, et al.
Bone Marrow Transplantation|November 20, 2024
Immunological reconstitution and infections after alloHCT - a comparison between post-transplantation cyclophosphamide, ATLG and non-ATLG based GvHD prophylaxisThomas Meyer, Kristina Maas-Bauer, Ralph Wäsch, et al.
Clinical Biochemistry|November 29, 2017
Cell-free DNA characteristics and chimerism analysis in patients after allogeneic cell transplantationJesus Duque-Afonso, Miguel Waterhouse, Dietmar Pfeifer, et al.
Annals of Hematology|March 3, 2016
Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCRMiguel Waterhouse, Marie Follo, Dietmar Pfeifer, et al.
Plos One|November 3, 2011
Differential sensitivity of ERBB2 kinase domain mutations towards lapatinibRama Krishna Kancha, Nikolas von Bubnoff, Natalie Bartosch, et al.
Leukemia Research|April 28, 2004
Imatinib mesylate (STI571) prevents the mutator phenotype of Bcr-Abl in hematopoietic cell linesHeiko van der Kuip, Alexandra Moehring, Lara Wohlbold, et al.
Haematologica|August 30, 2008
Imatinib and leptomycin B are effective in overcoming imatinib-resistance due to Bcr-Abl amplification and clonal evolution but not due to Bcr-Abl kinase domain mutationRama Krishna Kancha, Nikolas von Bubnoff, Cornelius Miething, et al.
Annals of Neurology|October 3, 2009
Primary central nervous system lymphoma in a patient treated with natalizumabAndreas Schweikert, Marcus Kremer, Florian Ringel, et al.
Molecular Oncology|December 17, 2023
A newly identified 45-kDa JAK2 variant with an altered kinase domain structure represents a novel mode of JAK2 kinase inhibitor resistanceSivahari Prasad Gorantla, Tony Andreas Mueller, Corinna Albers-Leischner, et al.
Pageof 25